The novel combination of astragaloside IV and formononetin protects from doxorubicin-induced cardiomyopathy

enhancing fatty acid metabolism

★ 5.0 · 52 reads

Sign in to save this
Request Code
ZLIB.IO18513001
Published
2022
Pages
1
Language
Unknown